VENUSREM

Venus Remedies Share Price

 

 

Start SIP in VENUSREM

Start SIP

Performance

  • Low
  • ₹783
  • High
  • ₹815
  • 52 Week Low
  • ₹270
  • 52 Week High
  • ₹840
  • Open Price₹801
  • Previous Close₹802
  • Volume41,267

Investment Returns

  • Over 1 Month + 16.35%
  • Over 3 Month + 76.59%
  • Over 6 Month + 81.22%
  • Over 1 Year + 155.57%

Smart Investing Starts Here Start SIP with Venus Remedies for Steady Growth!

Invest Now

Venus Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 15
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 1,053
  • P/B Ratio
  • 1.8
  • Average True Range
  • 40.99
  • EPS
  • 47.4
  • Dividend Yield
  • 0
  • MACD Signal
  • 53.51
  • RSI
  • 60.26
  • MFI
  • 52.41

Venus Remedies Financials

Venus Remedies Technicals

EMA & SMA

Current Price
₹788.05
-13.6 (-1.7%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹758.91
  • 50 Day
  • ₹666.27
  • 100 Day
  • ₹583.41
  • 200 Day
  • ₹503.23

Resistance and Support

795.35 Pivot Speed
  • R3 839.70
  • R2 827.35
  • R1 807.70
  • S1 775.70
  • S2 763.35
  • S3 743.70

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Venus Remedies has an operating revenue of Rs. 696.48 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 29% and 72% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 41% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 97 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venus Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-10 Quarterly Results
2025-08-01 Quarterly Results
2025-07-08 Others Inter-alia, to consider 1. Notice of 36th Annual General Meeting. 2. Boards Report for Financial Year 2024-2025. 3. Other business matters.
2025-05-26 Audited Results
2025-02-04 Quarterly Results

Venus Remedies F&O

Venus Remedies Shareholding Pattern

41.76%
1.86%
45.3%
11.08%

About Venus Remedies

  • NSE Symbol
  • VENUSREM
  • BSE Symbol
  • 526953
  • Chairman & Managing Director
  • Mr. Pawan Chaudhary
  • ISIN
  • INE411B01019

Similar Stocks to Venus Remedies

Venus Remedies FAQs

Venus Remedies share price is ₹788 As on 26 December, 2025 | 23:22

The Market Cap of Venus Remedies is ₹1053.4 Cr As on 26 December, 2025 | 23:22

The P/E ratio of Venus Remedies is 15 As on 26 December, 2025 | 23:22

The PB ratio of Venus Remedies is 1.8 As on 26 December, 2025 | 23:22

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23